BIOMARIN PHARMACEU BMRN (NASDAQ) $ 27.84 Change: -0.68 -2.44% | Volume: 2,410,928

BIOMARIN PHARMA - Fundamental Profile

Company Information

Ticker Symbol: BMRN
Exchange: NASD
Contact Info: 105 Digital Drive Novato CA 94949 415 506-6700
CEO/President: Jean Jacques Bienaime
Industry: Medical - Biomedical / Standard Industry Code: 2834
Description: BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin\'s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Share Information

Shares Outstanding: 98,550 (000) Market Value: 2,839,740 ($000)
Percentage of Inst.Shareholders: 89.54% Number of Inst.Shareholders: 2.60%
Last Quarter Sales: 64.17 ($Mil.) Last Quarter Net Income: 3.81 ($Mil.)
Last Quarter EPS: 0.04 P/E Ratio: 713
Most Recent Earnings: 0.10 on 08/05/08 Earnings Per Share: 0.04
Most Recent Split: Annual Dividend Rate: 0
Most Recent Dividend: Annual Dividend Yield: 0%
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
advertisement

Top Competitors

AMGEN +28.80 60.41
AMYLIN PHARMA I -56.90 21.11
GILEAD SCIENCES +15.20 47.85
BIOGEN IDEC INC -20.40 48.59
GENENTECH INC +33.90 96.64